Smith & Nephew plc (ADR)  

(Public, NYSE:SNN)   Watch this stock  
Find more results for SNN
31.84
+0.04 (0.13%)
Oct 24 - Close
NYSE real-time data - Disclaimer
Currency in USD
Range 31.70 - 31.90
52 week 25.55 - 40.36
Open 31.74
Vol / Avg. 150,072.00/563,739.00
Mkt cap 14.06B
P/E 27.40
Div/yield 0.22/1.76
EPS 1.16
Shares 893.78M
Beta 0.87
Inst. own 2%
Nov 11, 2014
Smith & Nephew PLC Capital Markets Event - 9:00AM EST - Add to calendar
Oct 30, 2014
Q3 2014 Smith & Nephew PLC Earnings Call - 9:15AM EDT - Add to calendar
Oct 30, 2014
Q3 2014 Smith & Nephew Earnings Release - 8:00AM EDT - Add to calendar
Sep 18, 2014
Smith & Nephew PLC at Bernstein Strategic Decisions Conference
Aug 1, 2014
Q2 2014 Smith & Nephew PLC Earnings Call - Webcast
Aug 1, 2014
Q2 2014 Smith & Nephew Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '14) 2013
Net profit margin 7.76% 12.78%
Operating margin 11.51% 18.62%
EBITD margin - 30.41%
Return on average assets 5.22% 9.70%
Return on average equity 8.53% 14.02%
Employees 14,000 -
CDP Score - 92 B

Address

15 Adam Street
LONDON, ENG WC2N 6LA
United Kingdom - Map
+44-20-74017646 (Phone)
+44-20-79303353 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Smith & Nephew plc is a global medical devices business operating in the markets for orthopaedic reconstruction and trauma, endoscopy (which includes arthroscopic procedures referred to as sports medicine) and advanced wound management. It operates in three segments: Orthopaedics, Endoscopy and Advanced Wound Management. It operates on a worldwide basis and has distribution channels in over 90 countries. Orthopaedic reconstruction implants include hip, knee and shoulder joints, as well as ancillary products, such as bone cement and mixing systems used in cemented reconstruction joint surgery. Endoscopy business develops and commercialises endoscopic (minimally invasive surgery) techniques, educational programmes and services. Advanced Wound Management business offers a range of products from initial wound bed preparation through to full wound closure. In May 2012, it acquired Kalypto Medical, Inc. In May 2014, the Company acquired ArthroCare Corporation.

Officers and directors

Olivier Bohuon Chief Executive Officer, Executive Director
Age: 55
Bio & Compensation  - Reuters
Julie Brown Chief Financial Officer, Executive Director
Age: 51
Bio & Compensation  - Reuters
Rodrigo Bianchi President, IRAMEA
Age: 54
Bio & Compensation  - Reuters
Michael G. Frazzette President - Advanced Surgical Devices
Age: 52
Bio & Compensation  - Reuters
R. Gordon Howe President - Global Operations
Age: 51
Bio & Compensation  - Reuters
Roger Teasdale President - Advanced Wound Management
Age: 46
Bio & Compensation  - Reuters
Francisco Canal Vega President - Latin America
Age: 52
Bio & Compensation  - Reuters
John W. Campo Chief Legal Officer
Age: 59
Bio & Compensation  - Reuters
Helen Maye Chief Human Resources Officer
Age: 54
Bio & Compensation  - Reuters
Cyrille Petit Chief Corporate Development Officer
Age: 43
Bio & Compensation  - Reuters